

Development and usefulness of transgenic rabbit models of inborn arrhythmogenic diseases

Citation for published version (APA):

Brunner, M. (2024). *Development and usefulness of transgenic rabbit models of inborn arrhythmogenic diseases*. [Doctoral Thesis, Maastricht University]. Maastricht University. <https://doi.org/10.26481/dis.20241209mb>

Document status and date:

Published: 01/01/2024

DOI:

[10.26481/dis.20241209mb](https://doi.org/10.26481/dis.20241209mb)

Document Version:

Publisher's PDF, also known as Version of record

Please check the document version of this publication:

- A submitted manuscript is the version of the article upon submission and before peer-review. There can be important differences between the submitted version and the official published version of record. People interested in the research are advised to contact the author for the final version of the publication, or visit the DOI to the publisher's website.
- The final author version and the galley proof are versions of the publication after peer review.
- The final published version features the final layout of the paper including the volume, issue and page numbers.

[Link to publication](#)

General rights

Copyright and moral rights for the publications made accessible in the public portal are retained by the authors and/or other copyright owners and it is a condition of accessing publications that users recognise and abide by the legal requirements associated with these rights.

- Users may download and print one copy of any publication from the public portal for the purpose of private study or research.
- You may not further distribute the material or use it for any profit-making activity or commercial gain
- You may freely distribute the URL identifying the publication in the public portal.

If the publication is distributed under the terms of Article 25fa of the Dutch Copyright Act, indicated by the "Taverne" license above, please follow below link for the End User Agreement:

www.umlib.nl/taverne-license

Take down policy

If you believe that this document breaches copyright please contact us at:

repository@maastrichtuniversity.nl

providing details and we will investigate your claim.

Download date: 19 Mar. 2025

Development and usefulness of transgenic rabbit models of inborn arrhythmogenic diseases

Addendum to the thesis by Michael Brunner, which will be defended on dec 9th, 2024:

Propositions:

- 1.) For arrhythmia research, rabbits are a markedly more useful model than mice.
[this thesis]
- 2.) Hormonal influences on the arrhythmogenic substrate can be demonstrated in transgenic rabbits leading to potential new approaches to treatment.
[this thesis]
- 3.) Pharmacological models of inborn arrhythmias are sometimes useful, but in many aspects not equivalent to genetic models. [this thesis]
- 4.) Overexpression (e.g., of a dominant negative) gene is a good model, but direct gene-editing would be closer to a perfect model. Until now, no Crispr/Cas or similar rabbit-model of arrhythmias has been created, but for CPVT or Brugada syndrome this might be the best (or only!) way to do it. [partially this thesis]
- 5.) Artificial intelligence will markedly change the way we diagnose diseases in the ECG, with applications way beyond cardiac diseases, and this will happen very, very rapidly.
- 6.) The phenotype of the same mutation in LQTS is variable and its characteristics depend on yet unknown factors, which are likely compensatory alterations of ion currents. Analyzing these factors might show options to alleviate symptomatic LQTS.
- 7.) Conduction system pacing should become the standard of care in most patients in need of ventricular stimulation by a pacemaker.
- 8.) The transgenic rabbit models (LQTS and SQTS) presented in this thesis already impacted science (and society), not to the least by enabling an in vivo study of gene therapy (suppression and replacement) which might – in some form or another be useful in humans one day. The ethical considerations of the first-in-man study to use a genetic therapy in patients with other treatment options will be at least as hard to solve as the technical problems of homogenous gene delivery.
[this thesis]